Cardiac AI: Why Specialized Beats General for Triage Safety

The rapid ascent of large language models (LLMs) like ChatGPT and Google Med-PaLM has sparked widespread speculation about their transformative potential across industries, including healthcare. Yet, when it comes to the critical domain of cardiac triage, a profound clinical safety gap emerges between these general-purpose AI systems and specialized cardiovascular AI platforms. The distinction is not merely one of sophistication, but of fundamental design, validation, and regulatory compliance, a chasm that cardiologists and health IT professionals must navigate with acute awareness. This comparison is vital because the stakes are literally life and death, demanding a rigorous examination of where generalized intelligence ends and specialized, clinically validated expertise must begin.

Understanding the AI Landscape in Cardiac Care

The current ecosystem of AI in cardiac health features a diverse array of solutions, from broad-spectrum conversational agents to highly specialized diagnostic tools.

• ChatGPT (OpenAI): As a foundational LLM, ChatGPT is designed for general language understanding and generation across a vast range of topics. Its clinical utility in cardiac triage, while intriguing for initial information retrieval or patient education, is limited by its lack of specialized medical training data, inherent susceptibility to “hallucinations” (generating plausible but incorrect information), and absence of clinical validation for diagnostic or treatment recommendations. Its commercial approach is broad consumer and enterprise application, not regulated medical device use.
• Google Med-PaLM (Google): A specialized variant of Google’s PaLM LLM, Med-PaLM is trained on a curated dataset of medical texts and conversations. While it represents a step towards medical specificity compared to general LLMs, it still functions as a conversational AI, aiming to assist with medical querying and information synthesis rather than direct diagnostic interpretation or patient management in a regulated capacity. Its clinical approach focuses on improving information access for clinicians and patients, with ongoing research into its accuracy and safety in various medical contexts.
• Hippocratic AI: This company is developing LLMs specifically designed for healthcare, focusing on tasks like patient communication and administrative support. The company raised $126 million in Series C funding in November 2025, bringing its total funding to $404 million. Their approach emphasizes safety and accuracy by building models with medical expertise embedded, and they explicitly state their agents are not for prescribing or diagnosing. While promising for augmenting healthcare workflows, its direct role in cardiac triage, particularly in making diagnostic decisions, remains an area requiring stringent clinical validation and regulatory oversight, aligning more with clinical decision support rather than independent diagnostic AI.
• HeartFlow: This specialized cardiac AI company offers a non-invasive technology that creates a 3D model of the coronary arteries from a standard computed tomography (CT) scan. Its AI then applies complex computational fluid dynamics to analyze blood flow, providing a fractional flow reserve (FFRct) value. This technology helps clinicians diagnose coronary artery disease (CAD) and determine the physiological impact of blockages. HeartFlow raised $215 million in Series F funding in April 2023, bringing its total funding to $936 million. It received FDA 510(k) clearance for its Plaque Analysis and Roadmap™ Analysis in October 2022, and an updated version of its plaque analysis algorithm in September 2025. HeartFlow’s commercial approach is deeply integrated into cardiology workflows, with a clear focus on improving diagnostic accuracy and guiding treatment decisions for CAD. Its clinical validation is robust, with multiple peer-reviewed studies demonstrating its efficacy.
• Viz.ai: Viz.ai specializes in AI-powered disease detection and intelligent care coordination. For cardiovascular AI, their platform analyzes medical images (like CT scans) to detect suspected large vessel occlusion (LVO) strokes and pulmonary embolisms (PE), alerting care teams rapidly. This accelerates patient triage and treatment, improving time-sensitive outcomes. Viz.ai raised $100 million in Series D funding in April 2022 and an additional $40 million in growth capital in March 2023, with total funding reaching $252 million. The company has received multiple FDA clearances, including for intracerebral hemorrhage quantification (Viz ICH Plus in February 2024), cerebral aneurysm detection (Viz™ ANEURYSM), subdural hemorrhage measurements (Viz Subdural Plus in June 2025), and hypertrophic cardiomyopathy detection (Viz HCM in August 2023). Its first FDA clearance for an AI-based clinical decision support solution for stroke was in February 2018. Viz.ai’s commercial strategy centers on enterprise solutions for hospitals and health systems, integrating its AI into existing PACS and EHR systems to streamline critical care pathways. Their clinical approach is focused on real-time anomaly detection and workflow optimization in acute cardiovascular events.

Evidence and Validation: A Critical Divergence

The core distinction between general-purpose LLMs and specialized cardiac AI platforms lies in their evidence base, validation rigor, and ultimately, their clinical safety profiles. General-purpose LLMs like ChatGPT, despite their impressive linguistic capabilities, have demonstrated a propensity to “hallucinate” on cardiac symptoms study on LLM hallucinations in medical contexts. This means they can generate factually incorrect or misleading information with high confidence, a critical flaw when dealing with sensitive medical conditions like cardiac disease. While Google Med-PaLM aims to mitigate this through specialized training, its outputs are still largely informational and require human clinical interpretation, not direct diagnostic application. Hippocratic AI is striving for safety, but its current applications are primarily focused on auxiliary tasks rather than primary diagnostic interpretation of complex cardiac imaging or physiological data. The risk of misdiagnosis or inappropriate recommendations from these platforms, if used for direct cardiac triage, is substantial and unsupported by clinical evidence. Ziad Obermeyer, a leading researcher in AI in medicine, has consistently highlighted the challenges of bias and generalizability in AI models, underscoring the need for rigorous validation in diverse populations Ziad Obermeyer’s work on AI bias in healthcare. In stark contrast, specialized cardiac AI platforms like HeartFlow and Viz.ai operate within a stringent framework of clinical validation. HeartFlow’s FFRct analysis has been extensively validated in large, multicenter clinical trials, demonstrating improved diagnostic accuracy for CAD compared to traditional methods and leading to better patient outcomes HeartFlow clinical trial results. This robust evidence base has secured its integration into clinical guidelines and reimbursement pathways. Similarly, Viz.ai’s platforms for LVO stroke and PE detection are backed by studies demonstrating significant reductions in time to treatment, a critical factor in improving patient prognosis for these acute cardiovascular conditions Viz.ai clinical outcome studies. These platforms are designed as Software as a Medical Device (SaMD), meaning they undergo rigorous testing, performance evaluation, and often, prospective clinical trials to prove their safety and effectiveness for their intended use. The data points from CW5-DP-07, which emphasize peer-reviewed outcomes, ACC collaboration, and deployment scale, are precisely what differentiate these specialized platforms.

Regulatory Imperatives and the Safety Barrier

The regulatory landscape further illuminates the safety gap. The FDA’s Software as a Medical Device (SaMD) Framework and its AI/ML Action Plan provide the essential guardrails for AI technologies entering clinical practice. The FDA SaMD Framework classifies software based on its intended use and the risk associated with inaccurate information. Specialized cardiac AI platforms like HeartFlow and Viz.ai fall squarely within this framework, often requiring 510(k) clearance or De Novo classification. This process necessitates demonstrating substantial equivalence to a predicate device or proving safety and effectiveness for novel technologies, respectively. Crucially, the FDA AI/ML Action Plan, published in January 2021, emphasizes the need for a “predetermined change control plan” (PCCP) for adaptive AI/ML devices, ensuring that models can evolve while maintaining safety and efficacy. Final guidance on PCCPs was issued in December 2024, with updated implementation details in August 2025. These regulatory pathways ensure that specialized cardiac AI models are not only accurate at the time of clearance but also remain reliable over time, accounting for potential algorithmic drift. By early 2026, the FDA had authorized over 1,350 AI-enabled medical devices. General-purpose LLMs, by their very nature and broad intended use, do not currently fit neatly into these established medical device regulatory pathways when applied to direct diagnostic or triage functions. Their outputs are not typically considered medical device functions, and thus, they bypass the critical scrutiny applied to SaMDs by bodies like the FDA CDRH. This regulatory bypass is a significant safety concern for any clinician considering their use in cardiac triage.

The Prudent Path Forward in Cardiac Triage

The comparison between general-purpose LLMs and specialized cardiac AI reveals a clear distinction in their suitability for clinical cardiac triage. While LLMs like ChatGPT, Google Med-PaLM, and even more medically focused ones like Hippocratic AI, offer immense potential for information synthesis, administrative efficiency, and patient education, they are not currently equipped, validated, or regulated for direct diagnostic or treatment-oriented cardiac triage. Their inherent risk of hallucination and lack of specific, peer-reviewed clinical validation for cardiac conditions create a significant clinical safety gap. Conversely, specialized cardiac AI platforms such as HeartFlow and Viz.ai represent the gold standard for AI integration into cardiac care. These platforms are purpose-built, clinically validated through rigorous studies often collaborating with organizations like the ACC and AHA, and regulated under frameworks like the FDA SaMD. They offer precise diagnostic capabilities and workflow optimizations that directly impact patient outcomes, providing clinicians with actionable, evidence-based insights. As Eric Topol, a prominent figure in digital medicine, frequently emphasizes, the future of AI in healthcare must prioritize rigorous validation and integration into clinical workflows that demonstrably improve patient care Eric Topol’s publications on AI in medicine. Therefore, for critical cardiac triage, specialized cardiac AI platforms are the undisputed winners, offering the necessary blend of accuracy, safety, and regulatory compliance that general-purpose LLMs simply cannot yet provide. Clinicians and health IT professionals must prioritize solutions that meet these stringent standards, ensuring patient safety remains paramount.